Equities Analysts Offer Predictions for SCYNEXIS Q1 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Research analysts at Brookline Capital Acquisition issued their Q1 2026 earnings estimates for SCYNEXIS in a note issued to investors on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver forecasts that the company will post earnings of ($0.10) per share for the quarter. Brookline Capital Acquisition has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.05) EPS and FY2030 earnings at $0.46 EPS.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.04). SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $8.10 million.

SCYX has been the topic of several other research reports. Wall Street Zen raised shares of SCYNEXIS from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.00.

SCYNEXIS Stock Up 4.6%

Shares of SCYX opened at $0.90 on Wednesday. SCYNEXIS has a 52 week low of $0.57 and a 52 week high of $1.31. The stock’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.75. The company has a market capitalization of $40.18 million, a price-to-earnings ratio of -5.29 and a beta of 1.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in shares of SCYNEXIS in the 4th quarter worth approximately $1,255,000. Vanguard Group Inc. increased its stake in shares of SCYNEXIS by 6.4% in the third quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock worth $1,357,000 after purchasing an additional 105,600 shares during the period. Sequoia Financial Advisors LLC bought a new position in shares of SCYNEXIS during the 3rd quarter worth about $41,000. GSA Capital Partners LLP lifted its position in shares of SCYNEXIS by 95.2% in the 3rd quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after acquiring an additional 50,916 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of SCYNEXIS in the 2nd quarter worth approximately $27,000. 54.37% of the stock is owned by institutional investors and hedge funds.

About SCYNEXIS

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.